<DOC>
	<DOCNO>NCT01799356</DOCNO>
	<brief_summary>We aim compare efficacy safety combination therapy oral ofloxacin , 400 mg twice daily , plus oral metronidazole , 500 mg twice daily , 14 day , moxifloxacin monotherapy , 400 mg daily , 14 day</brief_summary>
	<brief_title>Moxifloxacin Versus Ofloxacin Plus Metronidazole Uncomplicated Pelvic Inflammatory Disease : Multicenter Randomized Controlled Trials</brief_title>
	<detailed_description />
	<mesh_term>Pelvic Inflammatory Disease</mesh_term>
	<mesh_term>Pelvic Infection</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Women diagnose uncomplicated PID 2 . Patients age 14 45 3 . Pelvic tenderness vaginal discharge 1 . Urinary Tract Enfections 2 . Tuboovarian abscess complicate PID 3 . HÄ±story antibiotic treatment 4 . Other pelvic pain cause 5 . Endometriosis 6 . Delivery , abortion surgery within last month</criteria>
	<gender>Female</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Treatment , moksifloksasin</keyword>
</DOC>